Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by painful lumps, abscesses, and scarring, typically occurring in areas where skin rubs together, such as the armpits and groin.
Hidradenitis Suppurativa: Tibulizumab Study
We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 70 years old?
- Are you currently pregnant, breastfeeding, or planning to become pregnant during the study?
- Have you had major surgery in the past 4 weeks?
- Do you have a history of cancer or serious infections in the last 5 years?
- Are you taking any medications that affect your immune system, like steroids or biologics?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Tibulizumab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Fachklinik Bad Bentheim
Dermatology
Bad Bentheim, Germany
St. Josef-Hospital
Dermatology
Bochum, Germany
Klinikum Darmstadt GmbH
Dermatology
Darmstadt, Germany
Sponsor: Zura Bio Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.